EVIAGENICS acquires ALGANACT and becomes ALGAIA
VILLEJUIF, France – June 1st 2016: Eviagenics continues its metamorphosis with the acquisition of assets, know-how and team of Alganact SA, a French start-up company specialized in the development, characterization and production of specialty seaweed...
EVIAGENICS strengthens its management team
EVIAGENICS strengthens its management team and continues its metamorphosis Link to the Official Press Release Link to the “Formule verte” article
EVIAGENICS sells its flavonoid Biotech platform to Alderys
EVIAGENICS concluded the sale of its Flavonoid Biotech platform to Alderys, a well-established French Biotech firm located at Orsay Link to the Official Press Release Link to the “Formule verte” article Link to the “Nutra-ingredients”...
EVIAGENICS sells its Vanillin technology
EVIAGENICS concluded in June 2015 the sale of its yeast based Vanillin technology (and related patents) to a large industrial player. The terms and conditions of this transaction are confidential. Algaia is now concentrating its Biotech R&D efforts to specific...
EVIAGENICS raises 2.5m€ additional funding for its strategy
EVIAGENICS raises 2.5m€ additional funding from its current investors to deploy its strategy related to seaweed extracts .
EVIAGENICS starts an agreement with GELYMAR
GELYMAR enters into a commercial and development agreement with EVIAGENICS in Europe regarding seaweed extracts. Andres Hohlberg (Gelymar CEO) and Fabrice Bohin (EVIAGENICS CEO) January 22nd 2015: GELYMAR, a Chilean company currently being one of the top 4 global...
EVIAGENICS selected for PM’up regional grant
EVIAGENICS selected for PM’up regional grant. The purpose of this grant is to support the development of the Paris region SMB with high growth potential. The region selects projects with the greatest potential for value creation, employment, international development...